From Genomic Testing to Olaparib Treatment: Real-World Utilization and Outcomes in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer - Summary - MDSpire

From Genomic Testing to Olaparib Treatment: Real-World Utilization and Outcomes in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

  • By

  • Dianne Bosch

  • Kim J. M. van der Velden

  • Aart Beeker

  • Hendrik P. van den Berg

  • André M. Bergman

  • Maarten J. van der Doelen

  • Alfons J. M. van den Eertwegh

  • Mathijs P. Hendriks

  • Thomas M. A. Kerkhofs

  • Addy C. M. van de Luijtgaarden

  • Niven Mehra

  • Reindert J. A. van Moorselaar

  • Metin Tascilar

  • Walter L. Vervenne

  • Nir I. Weijl

  • Carin A. Uyl-de Groot

  • Peter F. A. Mulders

  • Malou C. P. Kuppen

  • Inge M. van Oort

  • May 9, 2026

Share

Objective:

To assess genomic testing practices and the clinical outcomes of olaparib monotherapy in a real-world cohort of BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) patients in the Netherlands, highlighting its significance in optimizing treatment strategies.

Key Findings:
  • Genomic testing was limited and inconsistently applied across medical centers, with specific statistics on testing rates.
  • Of the 35 eligible BRCAm patients, 27 received olaparib, showing better outcomes when treatment was initiated earlier in taxane-naïve settings, with data on survival rates.
  • The study highlighted the need for lowering the threshold for genomic testing to optimize personalized therapy, emphasizing the potential benefits.
Interpretation:

The findings suggest that earlier initiation of olaparib in taxane-naïve patients may lead to improved clinical outcomes, emphasizing the importance of consistent genomic testing practices and its implications for patient management.

Limitations:
  • Limited generalizability due to the study being conducted in a single country and potential biases in data collection.
  • Inconsistent application of genomic testing across different medical centers, which may affect the reliability of outcomes.
Conclusion:

The study underscores the necessity for improved genomic testing practices to enhance personalized treatment strategies in mCRPC patients, potentially leading to better patient outcomes.

Original Source(s)

From Genomic Testing to Olaparib Treatment: Real-World Utilization and Outcomes in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

  • by Dianne Bosch, Kim J. M. van der Velden, Aart Beeker, Hendrik P. van den Berg, André M. Bergman, Maarten J. van der Doelen, Alfons J. M. van den Eertwegh, Mathijs P. Hendriks, Thomas M. A. Kerkhofs, Addy C. M. van de Luijtgaarden, Niven Mehra, Reindert J. A. van Moorselaar, Metin Tascilar, Walter L. Vervenne, Nir I. Weijl, Carin A. Uyl-de Groot, Peter F. A. Mulders, Malou C. P. Kuppen, Inge M. van Oort

  • May 9, 2026

Related Content